APP and Alzheimer disease: We chose to focus on gene therapy targeting the APOE4 allele since this therapy is in the clinical trial stage; however, we recognize that attitudes regarding gene therapies to other potential targets including the APP, PS1 and PS2 genes would be a valuable addition to the analysis of attitudes toward gene therapy in AD.